<p>长期以来，医疗保健行业一直是经济的重要组成部分。根据麦肯锡公司的一份报告，预计医疗保健行业在 2022 年至 2027 年间将以 7% 的速度增长。许多医疗公司严重依赖临床试验，这些试验需要获得 FDA 批准才能上市。这使得预测公司未来表现变得极为困难。成功的试验可能带来数十亿美元的收入。然而，一次失败的试验很可能会导致股价下跌。因此，对于投资者来说，提前做好研究，只购买具有高增长潜力的医疗股票至关重要。以下是投资者现在应该购买的三家最佳医疗股票。</p>
<h2>百时美施贵宝（BMY）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>图片来源：Piotr Swat / Shutterstock.com</p>
<p>我们推荐的最佳医疗股票之一是 <strong>百时美施贵宝</strong>（纽约证券交易所：<strong>BMY</strong>）。这家制药巨头一直稳居市场前列，拥有多款药物每年创造数十亿美元的收入。此外，百时美施贵宝目前有多款药物正在临床试验中，未来十年可能取得巨大成功。其中包括治疗精神分裂症的 Eliquis KarXT。预计该药物将在下个月获得 FDA 的推荐。如果获批，它将成为首个新开发的精神分裂症治疗药物。据估计，这个市场在短短四年内将增长到超过 70 亿美元。目前，该股今年下跌超过 10%，同比下跌 20%。投资者应该在股价下跌时购买。</p>
<h2>AMN 医疗服务（AMN）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>图片来源：Casimiro PT / Shutterstock.com</p>
<p><strong>AMN 医疗服务</strong>（纽约证券交易所：<strong>AMN</strong>）是一家医疗护理设施公司。它提供医疗工作者，包括护士和行业专业人士，以临时方式供职。在医疗工作者短缺时，由于高需求，公司取得了巨大成功。对于那些寻找高风险、高回报医疗股票的投资者，AMN 应该在他们的关注列表中。</p>
<p>公司最近的财报看起来非常有前景。在 2024 年第二季度，AMN 每股收益为 98 美分，几乎比分析师预期高出 20 美分。这是 AMN 医疗服务连续第四个季度超过盈利预期。此外，AMN 的前瞻市盈率为 13.64 倍，低于市场上大多数竞争对手。在股价回升至 2022 年的最高价之前，投资者应该购买该股。</p>
<h2>Rapport Therapeutics（RAPP）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>图片来源：Shutterstock</p>
<p>名单上的最后一支股票是 <strong>Rapport Therapeutics</strong>（纳斯达克：<strong>RAPP</strong>），一家由 <strong>强生</strong>（纽约证券交易所：<strong>JNJ</strong>）支持的生物技术公司。该公司于今年 6 月 7 日上市，首次公开发行筹集了 1.54 亿美元。股价在上市首日超过 20 美元，截至目前，股价为 19.05 美元。虽然对这家新进入市场的公司还有很多需要了解的地方，但肯定会吸引许多投资者。</p>
<p>Rapport Therapists 目前正在开发一种专注性癫痫药物。第二阶段试验将在未来几个月开始，这意味着这家生物技术初创公司未来几年将会有令人兴奋的消息。特别是考虑到仅在美国就有超过三百万成年癫痫患者，这意味着这是一个有待探索的庞大市场。</p>
<p>_在本文发布日期，Andy Kim 在本文提及的证券中没有（直接或间接）任何持仓。本文中表达的观点属于作者本人，遵守 InvestorPlace.com 的发布准则。</p>
<p>_在本文发布日期，负责编辑在本文提及的证券中没有（直接或间接）任何持仓。</p>
<p>Andy 是一位自学投资者，对 ESG 和社会责任投资感兴趣。他管理过一家小型投资基金的投资组合，并创办了自己的研究公司。通过在 InvestorPlace 的自由撰稿，他希望找到并分享有前景的公司投资，以改善世界。</p>
<p>生物技术，医疗保健</p>

百时美施贵宝

<p>医疗保健行业预计在 2022 年至 2027 年间以 7% 的速度增长，使其成为投资者感兴趣的领域。三支值得考虑购买的医疗保健股票包括百时美施贵宝（BMY）、AMN 医疗服务（AMN）和 Rapport Therapeutics（RAPP）。百时美施贵宝在临床试验中拥有有前途的药物，而 AMN 医疗服务一直稳定地超过盈利预期。得到强生公司支持的 Rapport Therapeutics 正在开发一种专注性癫痫药物。这些股票在医疗保健行业具有高增长潜力</p>

<p>The healthcare industry has been a critical part of the economy for a long time. According to a McKinsey &amp; Company report, the healthcare industry is expected to grow at 7% from 2022 to 2027. Many healthcare companies heavily rely on trials, which need to be FDA approved in order to be put on the market. This makes it extremely hard to predict a company’s future performance. Successful trials could bring in potentially billions of dollars in revenue. However, a failed trial will likely result in stock-price decline. Thus, it is extremely important for investors to do prior research and only buy healthcare stocks with high growth potential. Below are the three best healthcare stocks investors should buy right now.</p>
<div class="lb-trans"><p>长期以来，医疗保健行业一直是经济的重要组成部分。根据麦肯锡公司的一份报告，预计医疗保健行业在 2022 年至 2027 年间将以 7% 的速度增长。许多医疗公司严重依赖临床试验，这些试验需要获得 FDA 批准才能上市。这使得预测公司未来表现变得极为困难。成功的试验可能带来数十亿美元的收入。然而，一次失败的试验很可能会导致股价下跌。因此，对于投资者来说，提前做好研究，只购买具有高增长潜力的医疗股票至关重要。以下是投资者现在应该购买的三家最佳医疗股票。</p>
</div><h2>Bristol-Myers Squibb (BMY)</h2>
<div class="lb-trans"><h2>百时美施贵宝（BMY）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Piotr Swat / Shutterstock.com</p>
<div class="lb-trans"><p>图片来源：Piotr Swat / Shutterstock.com</p>
</div><p>The first stock on our list of the best healthcare stocks to buy is <strong>Bristol-Myers Squibb</strong> (NYSE: <strong>BMY</strong>). The pharmaceutical powerhouse consistently ranks as one of the top companies on the market, and has several drugs that generate billions of dollars in revenue. Furthermore, Bristol-Myers Squibb has a number of drugs currently in clinical trials that could bring in huge success over the next decade. Among these is schizophrenia treatment Eliquis KarXT. The drug is expected to receive a recommendation from the FDA as early as next month. If it gets approved, it will be the first newly developed treatment for schizophrenia. That is a market that is estimated to grow to more than $7 billion in just four years. Right now, the stock is down over 10% this year alone and 20% year-over-year. Investors should buy while the stock is down.</p>
<div class="lb-trans"><p>我们推荐的最佳医疗股票之一是 <strong>百时美施贵宝</strong>（纽约证券交易所：<strong>BMY</strong>）。这家制药巨头一直稳居市场前列，拥有多款药物每年创造数十亿美元的收入。此外，百时美施贵宝目前有多款药物正在临床试验中，未来十年可能取得巨大成功。其中包括治疗精神分裂症的 Eliquis KarXT。预计该药物将在下个月获得 FDA 的推荐。如果获批，它将成为首个新开发的精神分裂症治疗药物。据估计，这个市场在短短四年内将增长到超过 70 亿美元。目前，该股今年下跌超过 10%，同比下跌 20%。投资者应该在股价下跌时购买。</p>
</div><h2>AMN Healthcare Services (AMN)</h2>
<div class="lb-trans"><h2>AMN 医疗服务（AMN）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Casimiro PT / Shutterstock.com</p>
<div class="lb-trans"><p>图片来源：Casimiro PT / Shutterstock.com</p>
</div><p><strong>AMN Healthcare Services</strong> (NYSE: <strong>AMN</strong>) is a medical care facilities company. It supplies healthcare workers, including nurses and industry professionals, on a temporary basis. It experienced huge success from high healthcare worker demand when there was a worker shortage. For those investors who are looking for high-risk, high-reward healthcare stocks, AMN should be on their radar.</p>
<div class="lb-trans"><p><strong>AMN 医疗服务</strong>（纽约证券交易所：<strong>AMN</strong>）是一家医疗护理设施公司。它提供医疗工作者，包括护士和行业专业人士，以临时方式供职。在医疗工作者短缺时，由于高需求，公司取得了巨大成功。对于那些寻找高风险、高回报医疗股票的投资者，AMN 应该在他们的关注列表中。</p>
</div><p>The company’s recent earnings reports look very promising. In Q2 2024, AMN reported earnings per share (EPS) of 98 cents, beating analyst’s estimates by almost 20 cents. This was the fourth consecutive quarter that AMN Healthcare Services beat the earnings estimate. Furthermore, AMN trades at 13.64 times forward price to earnings ratio, which is lower than the majority of its competitors in the market. Before it bounces back to its peak price from 2022, investors should buy the stock.</p>
<div class="lb-trans"><p>公司最近的财报看起来非常有前景。在 2024 年第二季度，AMN 每股收益为 98 美分，几乎比分析师预期高出 20 美分。这是 AMN 医疗服务连续第四个季度超过盈利预期。此外，AMN 的前瞻市盈率为 13.64 倍，低于市场上大多数竞争对手。在股价回升至 2022 年的最高价之前，投资者应该购买该股。</p>
</div><h2>Rapport Therapeutics (RAPP)</h2>
<div class="lb-trans"><h2>Rapport Therapeutics（RAPP）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Shutterstock</p>
<div class="lb-trans"><p>图片来源：Shutterstock</p>
</div><p>The last stock on the list is <strong>Rapport Therapeutics</strong> (NASDAQ: <strong>RAPP</strong>), a biotech company that is backed by <strong>Johnson &amp; Johnson</strong> (NYSE:<strong>JNJ</strong>). The company went public on June 7th of this year, and it raised $154 million in initial public offering. The stock price ended up to over $20 on the first day it went public, and as of writing, it goes for $19.05. While there is still lots to learn about the company as it is new to the market, there are certainly things that will attract many investors.</p>
<div class="lb-trans"><p>名单上的最后一支股票是 <strong>Rapport Therapeutics</strong>（纳斯达克：<strong>RAPP</strong>），一家由 <strong>强生</strong>（纽约证券交易所：<strong>JNJ</strong>）支持的生物技术公司。该公司于今年 6 月 7 日上市，首次公开发行筹集了 1.54 亿美元。股价在上市首日超过 20 美元，截至目前，股价为 19.05 美元。虽然对这家新进入市场的公司还有很多需要了解的地方，但肯定会吸引许多投资者。</p>
</div><p>Rapport Therapists is currently developing a focal epilepsy drug. The phase two trials should begin in the next few months, which means that there is going to be exciting news for the biotech startup for the upcoming years. This is especially exciting considering that in the U.S. alone, there are more than three million adult epilepsy patients, which means that it is a sizable market with room to explore.</p>
<div class="lb-trans"><p>Rapport Therapists 目前正在开发一种专注性癫痫药物。第二阶段试验将在未来几个月开始，这意味着这家生物技术初创公司未来几年将会有令人兴奋的消息。特别是考虑到仅在美国就有超过三百万成年癫痫患者，这意味着这是一个有待探索的庞大市场。</p>
</div><p><em>On the date of publication, Andy Kim did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com</em> <em>Publishing Guidelines</em> <em>.</em></p>
<div class="lb-trans"><p>_在本文发布日期，Andy Kim 在本文提及的证券中没有（直接或间接）任何持仓。本文中表达的观点属于作者本人，遵守 InvestorPlace.com 的发布准则。</p>
</div><p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div class="lb-trans"><p>_在本文发布日期，负责编辑在本文提及的证券中没有（直接或间接）任何持仓。</p>
</div><p>Andy is a self-taught investor who is interested in ESG and socially responsible investing. He has managed the portfolio of a small investment fund and started his own research firm. Through his freelance writing on InvestorPlace, he hopes to find and share promising investments in companies with the goal of bettering the world.</p>
<div class="lb-trans"><p>Andy 是一位自学投资者，对 ESG 和社会责任投资感兴趣。他管理过一家小型投资基金的投资组合，并创办了自己的研究公司。通过在 InvestorPlace 的自由撰稿，他希望找到并分享有前景的公司投资，以改善世界。</p>
</div><p>Biotech, Healthcare</p>
<div class="lb-trans"><p>生物技术，医疗保健</p>
</div>

2024 年 8 月最值得购买的三只医疗股